Moderna Shares Rise 4.5% Ahead of Melanoma Trial Results

Moderna shares closed up 4.51% Thursday at $236.50, nine days before the scheduled presentation of detailed Phase 3 results for its personalized melanoma treatment with Merck. The stock gained $10.20 from its previous close of $226.30. Moderna had also reached a 52-week high on Oct. 9, when its shares rose just over 14% to close at $225 in a previous session . The INTerpath-001 trial tested intismeran autogene, also known as V940 or mRNA-4157, with pembrolizumab (Keytruda) after surgery in patients with completely resected stage IIB-IV melanoma. The investigational mRNA treatment is individualized using mutations found in each patient’s tumor. The Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.